M0443

Mirtazapine

Name: Mirtazapine
Brand: SIGMA

≥98% (HPLC), 5-HT2 antagonist; 5-HT3, H1 and α2 antagonist, powder

동의어(들):

1,2,3,4,10,14b-Hexahydro-2-methylpyrazino[2,1-a]pyrido[2,3-c][2]benzazepine

로그인조직 및 계약 가격 보기

크기 선택

제품정보 (DICE 배송 시 비용 별도)

실험식(Hill 표기법):

C₁₇H₁₉N₃

CAS 번호:

85650-52-8

Molecular Weight:

265.35

MDL number:

MFCD00865427

UNSPSC 코드:

12352200

PubChem Substance ID:

24724531

NACRES:

NA.77

주요 문서

모든 문서 보기

기술 서비스

도움이 필요하신가요? 저희 숙련된 과학자 팀이 도와드리겠습니다.

도움 문의

기술 서비스

도움이 필요하신가요? 저희 숙련된 과학자 팀이 도와드리겠습니다.

도움 문의

제품 이름

Mirtazapine, ≥98% (HPLC)

Quality Level

100

분석

≥98% (HPLC)

양식

powder

색상

white

solubility

DMSO: 8 mg/mL, clear

SMILES string

CN1CCN2C(C1)c3ccccc3Cc4cccnc24

InChI

1S/C17H19N3/c1-19-9-10-20-16(12-19)15-7-3-2-5-13(15)11-14-6-4-8-18-17(14)20/h2-8,16H,9-12H2,1H3

InChI key

RONZAEMNMFQXRA-UHFFFAOYSA-N

유전자 정보

human ... ADRA2A(150), ADRA2B(151), ADRA2C(152), DRD2(1813), DRD3(1814), DRD4(1815), HRH1(3269), HTR1A(3350), HTR2A(3356), HTR2C(3358), HTR7(3363)
mouse ... Slc6a2(20538)
rat ... Adra1a(29412), Drd1a(24316), Drd2(24318), Htr1a(24473), Htr2a(29595), Htr2c(25187), Slc6a3(24898), Slc6a4(25553)

유사한 제품을 찾으십니까? 방문 제품 비교 안내

생화학적/생리학적 작용

Mirtazapine is a noradrenergic and specific serotonergic antidepressant (NaSSA). Mirtazapine agonizes selective adrenergic and serotonergic receptors so that both NE release and 5-HT_1A mediated serotonergic signaling are increased.

픽토그램

GHS07

신호어

Warning

유해 및 위험 성명서

H302,H336

예방조치 성명서

P261 - P264 - P270 - P271 - P301 + P312 - P304 + P340 + P312

Hazard Classifications

Acute Tox. 4 Oral - STOT SE 3

표적 기관

Central nervous system

Storage Class Code

11 - Combustible Solids

WGK

WGK 3

Flash Point (°F)

Not applicable

Flash Point (°C)

Not applicable

개인 보호 장비

Eyeshields, Gloves, type N95 (US)

가장 최신 버전 중 하나를 선택하세요:

시험 성적서(COA)

Lot/Batch Number

적합한 버전을 찾을 수 없으신가요?

특정 버전이 필요한 경우 로트 번호나 배치 번호로 특정 인증서를 찾을 수 있습니다.

COA 검색

이 제품을 이미 가지고 계십니까?

문서 라이브러리에서 최근에 구매한 제품에 대한 문서를 찾아보세요.

문서 라이브러리 방문

Mirtazapine for treatment of depression and comorbidities in Alzheimer disease.

M A Raji et al.

The Annals of pharmacotherapy, 35(9), 1024-1027 (2001-09-28)

Depression in patients with Alzheimer disease is a treatable cause of functional decline, caregiver burden, and mortality. It is often associated with severe weight loss, insomnia, and anxiety. These symptoms independently and collaboratively further worsen the prognosis of these vulnerable

A review of the pharmacological and clinical profile of mirtazapine.

S A Anttila et al.

CNS drug reviews, 7(3), 249-264 (2001-10-19)

The novel antidepressant mirtazapine has a dual mode of action. It is a noradrenergic and specific serotonergic antidepressant (NaSSA) that acts by antagonizing the adrenergic alpha2-autoreceptors and alpha2-heteroreceptors as well as by blocking 5-HT2 and 5-HT3 receptors. It enhances, therefore

Low doses of alpha 2-adrenoceptor antagonists augment spinal morphine analgesia and inhibit development of acute and chronic tolerance.

B Milne et al.

British journal of pharmacology, 155(8), 1264-1278 (2008-09-23)

Ultra-low doses of opioid receptor antagonists augment spinal morphine antinociception and block the induction of tolerance. Considering the evidence demonstrating functional and physical interactions between the opioid and alpha(2)-adrenoceptors, this study investigated whether ultra-low doses of alpha(2)-adrenoceptor antagonists also influence

Managing the side effects associated with commonly used treatments for bipolar depression.

David E Kemp

Journal of affective disorders, 169 Suppl 1, S34-S44 (2014-12-24)

The most commonly used pharmacologic therapies for bipolar depression are mood stabilizers, atypical antipsychotics, and antidepressants. This paper reviews common side effects associated with these medications and provides recommendations for managing adverse medication effects in clinical practice. Narrative review based

The association of proopiomelanocortin polymorphisms with the risk of major depressive disorder and the response to antidepressants via interactions with stressful life events.

Hun Soo Chang et al.

Journal of neural transmission (Vienna, Austria : 1996), 122(1), 59-68 (2014-12-03)

Hyperactivity of the hypothalamic-pituitary-adrenal (HPA) axis is among the most consistent neuroendocrine abnormalities in major depressive disorder (MDD). The peptide adrenocorticotropin hormone (ACTH) mediates HPA axis function during stress and is encoded by the proopiomelanocortin (POMC) gene polycistronically. After screening

모든 관련된 서류 보기

Mirtazapine

≥98% (HPLC), 5-HT2 antagonist; 5-HT3, H1 and α2 antagonist, powder

크기 선택

제품정보 (DICE 배송 시 비용 별도)

주요 문서

속성

제품 이름

Quality Level

분석

양식

색상

solubility

SMILES string

InChI

InChI key

유전자 정보

관련 카테고리

설명

생화학적/생리학적 작용

안전성 정보

픽토그램

신호어

유해 및 위험 성명서

예방조치 성명서

Hazard Classifications

표적 기관

Storage Class Code

WGK

Flash Point (°F)

Flash Point (°C)

개인 보호 장비

문서

시험 성적서(COA)

이 제품을 이미 가지고 계십니까?

관련 참고 논문

관련 참고 프로토콜

관련 콘텐츠

기술 서비스